PBYI - Puma Biotechnology

-

$undefined

N/A

(N/A)

Puma Biotechnology NasdaqGS:PBYI Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Location: 10880 Wilshire Boulevard, Los Angeles, CA, 90024, United States | Website: https://www.pumabiotechnology.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

136.8M

Cash

93.17M

Avg Qtr Burn

N/A

Short % of Float

7.68%

Insider Ownership

15.49%

Institutional Own.

64.31%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NERLYNX Details
Breast cancer, Sexual desire disorder, Sexual dysfunction

Approved

Quarterly sales

NERLYNX Details
Breast cancer, Cancer, ER+/HER2- breast cancer, Solid tumor/s

Approved

Quarterly sales

Neratinib Details
Cervical cancer, Infectious disease, Catheter related blood stream infections

Phase 2

Data readout

Alisertib Details
ER+/HER2- breast cancer, Breast cancer, Cancer

Phase 2

Data readout

Alisertib Details
Cancer, Small cell lung cancer

Big Mover™

Susp. Mover™

Phase 2

Data readout

Phase 2

Update

Neratinib Details
Lung cancer, Non-small cell lung carcinoma

Phase 2

Update

Neratinib Details
Bile duct disease, Cancer

Phase 2

Update

Neratinib (HKI-272) + fulvestrant + trastzuzumab Details
Metastatic breast cancer, Breast cancer, Metastatic breast cancer to brain

Phase 2

Update

Alisertib (2 combo trials) Details
Breast cancer, ER+/HER2- breast cancer

Phase 2

Update

Alisertib Details
Cancer, Non-small cell lung carcinoma

Phase 1/2

Update

Alisertib+pembrolizumab Details
Head and neck squamous cell carcinoma, Cancer

Phase 1/2

Update